**What was known?**

Sirolimus is a novel drug belonging to the class of mTOR inhibitors and has been successfully tried topically in the management of angiofibromas associated with tuberous sclerosis.

Introduction {#sec1-1}
============

One of the most obvious cutaneous manifestations of tuberous sclerosis (TSC) is facial angiofibromas, which start appearing at 3 to 4 years of age. The number and size of angiofibromas varies markedly between patients, but they have the potential to become extremely unsightly. Typically, facial angiofibromas do not improve spontaneously and are frequently treated for the disfigurement.

Current treatments for facial angiofibromas include vascular lasers, ablative lasers and physically destructive techniques such as shave excision and electrodessication. Despite this proactive and costly approach, the outcomes are often less than satisfactory.

Oral sirolimus has already been used for the renal and neurological manifestations of TSC. In recent years it has been administered topically in varying concentrations for treatment of angiofibromas associated with TSC with good results. This is possibly the first report of the use of topical sirolimus in an Indian patient. The article further discusses the problems encountered with the use of the drug in the Indian scenario.

Case Report {#sec1-2}
===========

A 17-year-old female, a known case of TSC, presented to the outpatient department for the cosmetic treatment of disfiguring facial angiofibromas since 5 years of age. Dermatological examination revealed several other cutaneous manifestations characteristic of the disease apart from angiofibromas, namely ash leaf macules, shagreen plaque on the back and confetti like hypopigmented macules on the trunk. The patient also had history of convulsions and mental retardation. She had no known internal hamartomatous lesions.

She had undergone multiple sessions of electrodesiccation earlier with recurrence of lesions. In order to avoid an invasive procedure and its inherent complications, it was planned to start the patient on topical sirolimus.

Currently sirolimus is available in the international market in two formulations: Rapamune^®^ oral solution (60 mg per 60 ml in an amber colored bottle) and Rapamune^®^ tablet available in 1 mg and 2 mg strengths. Topical formulation of sirolimus is unavailable till date. Oral solution available commercially has been used topically as it is, or as a compounded product. Since there is no oral solution of sirolimus available in India, crushed tablets of sirolimus (Rapacan-1^®^, Biocon, India) were compounded in white soft paraffin using basic pharmacy equipment.

Prior to starting treatment, the complete blood count, hepatic and renal parameters of the patient were done and they were found to be normal. Since there are no available reports of tolerability of sirolimus in the Indian setting, it was thought prudent to start sirolimus in a low concentration of 0.1% and further increase the concentration according to the tolerability of the patient. Also, starting at a lower concentration would lower the cost of the medication for the patient, ensuring better patient compliance.

The patient was instructed to apply the ointment twice daily after washing and drying the face completely. After using the 0.1% preparation for 3 months, there was a definite decrease in the erythema as well as the size of the angiofibromas \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\]. Encouraged by the results; in an attempt to accelerate the response, the concentration of sirolimus was increased to 1% which was used for a period of a month with a definite decrease in the size as well as number of angiofibromas with substantial decrease in the erythema \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].
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The patient did not experience any cutaneous adverse effects throughout the treatment with topical sirolimus. As this report is being written, the patient is currently on treatment with 1% sirolimus ointment.

The complete blood count, renal and hepatic profile of the patient was monitored every 2 months and was found to be normal. It was not possible to measure the systemic absorption of the sirolimus on account of cost constraints.

Discussion {#sec1-3}
==========

TSC is an autosomal dominant genodermatosis characterized by development of hamartomatous tumors in multiple organs including brain, skin, kidney, heart and lungs. Facial angiofibromas are the most visible and unsightly of all the cutaneous manifestations of TSC and they are seen in up to 80% of the cases. They often result in a negative psychological impact on pediatric patients and stigmatization of their families.

Current treatment modalities include vascular lasers, ablative lasers and other destructive techniques such as shave excision, cryosurgery, dermabrasion, photodynamic therapy and electrodesiccation. Despite proactive and costly approaches, there is no sustained efficacy in the long term and the risks of complications like scarring continue to exist. Sedation utilized for these procedures poses a risk because of the underlying seizure disorders in these patients, so does anti epileptic loading and prolonged intubation.

Sirolimus is a lipophilic macrocyclic lactone which was first isolated from a soil bacterium *Streptomyces hygroscopicus* in Rapa Nui (Easter Island) in 1965, hence the old name Rapamycin. Sirolimus belongs to a novel class of anticancer drugs known as mTOR (mammalian target of Rapamycin) inhibitors.\[[@ref1]\]

Sirolimus and the related mTOR inhibitor everolimus have been used as a targeted therapy for the renal and neurological manifestations of TSC.\[[@ref2][@ref3][@ref4][@ref5][@ref6]\] A patient of TSC who was receiving oral sirolimus after undergoing renal transplantation had pronounced regression of her cutaneous angiofibromas and this triggered its use as a topical agent, in an attempt to minimize systemic toxicity.

In patients with TSC, the mTOR is aberrantly activated in fibroblast like cells located within the dermal layer of the skin. These cells produce an epidermal growth factor, epiregulin, which stimulates epidermal cell proliferation.\[[@ref7]\] Hence, epidermal cells are produced at a faster rate than the ability to slough the dead cells from the skin surface. This overproduction of skin cells in conjunction with angiogenesis results in initial appearance and continued progression of facial angiofibromas over time. Angiofibromas of TSC shows prominent vascular component owing to increased expression of angiogenic factors like vascular endothelial growth factor (VEGF) and mTOR overactivation that promotes angiogenesis. Sirolimus binds with high specificity to mTOR and this binding results in inhibition of mTOR activity and ultimately downregulation of cell growth.\[[@ref8]\] It also inhibits progression from G1 phase to S phase, suppresses T lymphocyte and antibody production, and inhibits keratinocytic proliferation and neutrophilic inflammatory activity\[[@ref9][@ref10]\] Also, inhibition of the mTOR pathway decreases output of VEGF by inhibiting hypoxia--inducible factor expression and by directly repressing VEGF-stimulated endothelial cell proliferation.\[[@ref11]\]

Sirolimus has a molecular weight of 914.2 grams/mol, allowing for it to be absorbed through the superficial layers of the epidermis to the deep dermal layer implicated in the development of facial angiofibromas.\[[@ref12]\] Growing tumors which are probably due to greater proliferative component during early stages of life, could be more sensitive to the inhibitory action of sirolimus on mTOR and hence it is justifiable to initiate treatment as soon as the angiofibromas start to appear in early childhood.

Various investigators have used different concentrations of topical sirolimus for varying duration for the management of facial angiofibromas \[[Table 1](#T1){ref-type="table"}\].
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Hence, topical sirolimus is an effective treatment for angiofibromas especially in young children with flatter lesions, with the preparation formulated in petrolatum being well tolerated with no adverse effects. It is also cost effective if compared to hospital admission for laser therapy under general anesthesia with due risks.

The treatment considerations that would probably be more relevant in the Indian sitting are:

High cost of the medication---When the concentration of the medication was increased to 1%, the expenditure of the patient can be more than Rs 200 per day which is very high for economically strained conditions existing in IndiaIt is practical to use commercially available oral solution of Sirolimus, since compounding pharmacies are not always readily accessible and the stability and efficacy of the compounded preparation cannot be ensured. Since oral solution was not available a topical preparation using crushed tablets of sirolimus was used in this caseCutaneous irritation or burning sensation has been mentioned in the literature as the most common side effect after topical sirolimus. It has been advised to co-prescribe topical hydrocortisone 1% or desonide 0.05% lotion to counteract irritation and ensure compliance.\[[@ref20]\] In this case, the patient tolerated the preparation very wellThough topically applied Sirolimus has minimal systemic absorption, it should have been monitored using chromatographic and immunoassay methodologies, which was not possible in a resource-constrained settingThe duration of treatment and the chances of recurrence are not defined. This makes the counseling of the patient difficult.

Thus, randomized controlled trials are necessary to enable us to confirm the efficacy of this treatment, its long term safety, the optimal dosage and possibility of reappearance once the drug is withdrawn. Also, given the small number of cases described to date, the most suitable presentation of the product has not yet been determined.

**What is new?**

This is possibly the first case report of use of topical sirolimus in an Indian patient.
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